DRUG · Mapped RxNorm record
eribulin mesylate
Normalized identity: eribulin mesylateView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
NCT01372579
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
carboplatin
Normalized identity: carboplatinView linked drug · Find medicine records ·
Find other trials using this name
PROCEDURE · Unmapped registry intervention
biopsy
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedCarboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HER2-negative Breast Cancerunresolved
Stage IA Breast Cancerunresolved
Stage IB Breast Cancerunresolved
Stage II Breast Cancerunresolved
Stage IIIA Breast Cancerunresolved
Stage IIIB Breast Cancerunresolved
Stage IIIC Breast Cancerunresolved
Interventions
eribulin mesylateDRUG · verified · RxNorm: eribulin mesylate
carboplatinDRUG · verified · RxNorm: carboplatin
biopsyPROCEDURE
Sponsors & collaborators
Northwestern Universitylead sponsor
Eisai Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01372579 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.